News
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...
2h
Stocktwits on MSNThis Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees OpportunityWells Fargo on Thursday raised its price target on Sarepta Therapeutics, Inc. (SRPT) to $50 from $48 after the company’s ...
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...
3h
Barchart on MSNStocks Rally on Positive Tariff News ad Rate Cut HopesThe S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.39%, and the Nasdaq ...
Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...
Scientists have found that lithium orotate — which is different from the kind of lithium typically used to treat mental health conditions — not only stopped the brain disease in mice but also reversed ...
Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the Cambridge, ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results